Where is 360Ids located?

360Ids is headquartered in Germany.

Is 360Ids a funded company?

360Ids is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does 360Ids rank among its competitors?

360Ids ranks 2187th amongst 1966 active competitors, of which 451 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of 360Ids?

360Ids' top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

360Ids - 2026 Company Profile & Competitors

Company Details

Provider of development, industrialization, and manufacturing solutions for life science devices. The company supports product and development concepts, business planning, and risk management. It offers services including innovation, concept development, industrialization, and life cycle management. The company also provides supplier and quality management, including process and documentation management.

Key Metrics

Location

Germany

Stage

Unfunded

Ranked

2187^th among 2677 competitors

Similar Companies

Antheia & 2675 more

View 360Ids' full profile

360Ids has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 360Ids include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of 360Ids, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Sequoia Capital & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
8th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
9th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, F-Prime Capital & 22 others	61/100
2187th	360Ids Germany, Unfunded	Provider of development, industrialization, and manufacturing solutions for life science devices	-	-	16/100